| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175535-100μg |
100μg |
现货  |
| |
| Ab175535-1mg |
1mg |
现货 |
|
| 产品名称 | Faricimab (anti-ANG2&VEGFA), 血管生成素-2 抑制剂 |
|---|---|
| 别名 | 法瑞西单抗 | 法利西单抗（抗-AG2 & VEGFA） | 法瑞西单抗 | ANG2抗体 | ANG2单克隆抗体 | ANG2药靶抗体 | VEGFA抗体 | VEGFA单克隆抗体 | VEGFA药靶抗体 | Angiopoietin-2抗体 | Angiopoietin-2单克隆抗体 | Angiopoietin-2药靶抗体 | VPS51抗体 | VPS51单克隆抗体 | VPS51药靶抗体 | ANGPT2抗体 | ANGPT2单克隆抗体 | ANGPT2药靶抗体 |
| 英文别名 | ANG2 antibody | ANG3 antibody | Another new gene 2 protein antibody | C11orf3 antibody | chromosome 11 open reading frame 2 antibody | Fat free homolog antibody | ffr antibody | FFR_HUMAN antibody | FFR|FLJ13879 antibody | FLJ36472 antibody | Protein fat- |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
| 生化机理 | ANG2: Required for both Golgi structure and vesicular trafficking, and ultimately lipid transport. VEGFA: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
| 宿主种属 | 人(Human) |
| 特异性 | VPS51 & VEGFA |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 血管生成素-2 抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa - lambda |
| SDS-PAGE | 180 kDa |
| 纯化方法 | Ion Exchange Chromatography |
| 储存缓冲液 | PBS, pH 7.4,Contains no stabilizers or preservatives. |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1607793-29-2 |
| 分子类型 | 抗体 |
Faricimab (anti-ANG2&VEGFA) (Ab175535) - ELISA
Immobilized Recombinant Human VEGFA protein (rp155965) at 1.0 μg/mL can bind Faricimab (anti-ANG2&VEGFA) (Ab175535) with the EC50 of 60.39 ng/mL.
Faricimab (anti-ANG2&VEGFA) (Ab175535) - SEC
The purity of Faricimab (anti-ANG2&VEGFA) (Ab175535) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 ZJ25F0218539 |
分析证书 | Ab175535 |
| ZJ25F0218540 |
分析证书 | Ab175535 |
¥619.90
| 1. Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J et al.. (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.. EMBO Mol Med, 8 (11): (1265-1288). [PMID:27742718] |
| 2. Nicolò M, Ferro Desideri L, Vagge A, Traverso CE. (2021) Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.. Expert Opin Investig Drugs, (1-8). [PMID:33471572] |
| 3. Foxton RH, Uhles S, Grüner S, Revelant F, Ullmer C. (2019) Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization.. EMBO Mol Med, 11 (5): [PMID:31040126] |
首页
400-620-6333
